Abstract:
Radiopharmaceutical therapy has been widely adopted owing primarily to the
development of novel radiopharmaceuticals. To fully utilize the potential of
these RPTs in the era of precision medicine, therapy must be optimized to the
patient’s tumor characteristics. The vastly disparate dosimetry methodologies
need to be harmonized as the first step towards this. Multiple factors play a
crucial role in the shift from empirical activity administration to patient-specific
dosimetry-based administrations from RPT. Factors such as variable responses
seen in patients with presumably similar clinical characteristics underscore the
need to standardize and validate dosimetry calculations. These efforts
combined with ongoing initiatives to streamline the dosimetry process
facilitate the implementation of radiomolecular precision oncology. However,
various challenges hinder the widespread adoption of personalized dosimetrybased activity administration, particularly when compared to the more
convenient and resource-efficient approach of empiric activity administration.
This review outlines the fundamental principles, procedures, and
methodologies related to image activity quantification and dosimetry with a
specific focus on 177Lutetium-based radiopharmaceuticals.
